Medios AG (ILM1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medios AG (ILM1) has a cash flow conversion efficiency ratio of 0.021x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€10.96 Million ≈ $12.81 Million USD) by net assets (€519.70 Million ≈ $607.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ILM1 market cap overview for the company's overall valuation and market capitalisation.
Medios AG - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Medios AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Medios AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medios AG ranked by their cash flow conversion efficiency. Explore ILM1 cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jinpu Landscape Architecture Co.Ltd.
SHE:301098
|
N/A |
|
Shandong Sino-Agri United Biotechnology Co Ltd
SHE:003042
|
-0.034x |
|
STEP Energy Services Ltd
TO:STEP
|
0.058x |
|
Jumbo Interactive Ltd
AU:JIN
|
0.185x |
|
Vimta Labs Limited
NSE:VIMTALABS
|
0.164x |
|
Ganesha Ecosphere Limited
NSE:GANECOS
|
0.010x |
|
Alvopetro Energy
V:ALV
|
0.129x |
|
Jiangsu Lanfeng Bio-chemical Co Ltd
SHE:002513
|
-0.330x |
Annual Cash Flow Conversion Efficiency for Medios AG (2010–2025)
The table below shows the annual cash flow conversion efficiency of Medios AG from 2010 to 2025. View current stock price of Medios AG for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €514.22 Million ≈ $601.18 Million |
€43.00 Million ≈ $50.27 Million |
0.084x | -42.08% |
| 2024-12-31 | €510.19 Million ≈ $596.47 Million |
€73.67 Million ≈ $86.12 Million |
0.144x | +312.59% |
| 2023-12-31 | €468.81 Million ≈ $548.08 Million |
€16.41 Million ≈ $19.18 Million |
0.035x | -57.76% |
| 2022-12-31 | €448.05 Million ≈ $523.81 Million |
€37.12 Million ≈ $43.40 Million |
0.083x | -46.92% |
| 2021-12-31 | €394.16 Million ≈ $460.82 Million |
€61.52 Million ≈ $71.92 Million |
0.156x | +158.32% |
| 2020-12-31 | €142.43 Million ≈ $166.51 Million |
€-38.12 Million ≈ $-44.56 Million |
-0.268x | -4762.04% |
| 2019-12-31 | €81.63 Million ≈ $95.43 Million |
€-449.29K ≈ $-525.26K |
-0.006x | +87.62% |
| 2018-12-31 | €70.50 Million ≈ $82.42 Million |
€-3.14 Million ≈ $-3.67 Million |
-0.044x | -348.97% |
| 2017-12-31 | €45.68 Million ≈ $53.40 Million |
€816.00K ≈ $953.99K |
0.018x | +138.51% |
| 2016-12-31 | €34.10 Million ≈ $39.86 Million |
€-1.58 Million ≈ $-1.85 Million |
-0.046x | +84.92% |
| 2015-12-31 | €323.78K ≈ $378.53K |
€-99.64K ≈ $-116.49K |
-0.308x | -- |
| 2014-12-31 | €0.00 ≈ $0.00 |
€13.30K ≈ $15.55K |
x | -- |
| 2013-12-31 | €7.81K ≈ $9.13K |
€103.36K ≈ $120.84K |
13.241x | +10691.51% |
| 2012-12-31 | €172.97K ≈ $202.22K |
€21.22K ≈ $24.81K |
0.123x | +157.35% |
| 2011-12-31 | €376.75K ≈ $440.46K |
€-80.60K ≈ $-94.23K |
-0.214x | -1872.06% |
| 2010-12-31 | €341.07K ≈ $398.75K |
€-3.70K ≈ $-4.33K |
-0.011x | -- |
About Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and p… Read more